Published September 9, 2026 | Version v1
Journal article Open

Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent

Description

Lung cancer with multiorgan metastasis remains the leading cause of cancer death. Current CT imaging and biopsy are suboptimal for detecting early tumors or subclinical metastases. We address this gap using LUAD with LKB1/STK11 inactivation, which alters collagen via focal adhesion kinase activation. Collagen I overexpression in the tumor microenvironment and invasive edge was identified as a biomarker. We developed hProCA32.Collagen, a protein MRI contrast agent targeting collagen I, which exhibits 10-fold higher relaxivity than clinical GBCAs, with strong Gd3+ binding, high stability, and low toxicity risk. Precision MRI with hProCA32.Collagen enables early, noninvasive detection and quantification of lung tumors and metastases with improved contrast, outperforming CT and standard MRI. This is a demonstration of simultaneous MRI detection of primary tumors and metastases in the lung and adrenal glands, with collagen mapping. This approach offers a radiation-free tool for early diagnosis, staging, and monitoring in LUAD.

Data availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. No custom code was generated or used in this study. No new materials were generated in this study.

Files

sciadv.adz6815.pdf

Files (6.6 MB)

Name Size Download all
md5:31722f7cd6c7717866d0f225f51c194c
3.4 MB Preview Download
md5:5725b4c3062fab47928b1d8848ef8359
3.3 MB Preview Download

Additional details

Funding

National Institutes of Health
S10OD027045
National Institutes of Health
33CA235319
National Institutes of Health
R42AA112713
National Institutes of Health
R42CA183376
National Institutes of Health
1R01EB007268
National Institutes of Health
R01CA203928
National Institutes of Health
R01CA194027
National Institutes of Health
InLighta BioSciences R42AA025863
National Institutes of Health
InLighta BioSciences R42CA183376
National Institutes of Health
InLighta BioSciences 1R44CA268403-01A1
National Institute of Diabetes and Digestive and Kidney Diseases
InLighta BioSciences R01 DK126080-01A1
National Institutes of Health
InLighta BioSciences 5P01CA257906
National Institutes of Health
InLighta BioSciences P30CA138292
National Institutes of Health
InLighta BioSciences UT2AA028659-01
Georgia State University
MBD fellowship
Georgia State University
CDT fellowship

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Radiation and Cellular Oncology
Center(s) or Institute(s)
Comprehensive Cancer Center